Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desmopressin ODT for Nocturia in Men
NCT01262456Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Feb 2011
- Primary completion
- Jan 2012
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of desmopressin in nocturia (3 arms), sponsored by Ferring Pharmaceuticals. Primary endpoints: Change From Baseline in Mean Number of Nocturnal Voids Averaged Over a 3-Month Period and Adjusted Probability of Participants Achieving a >33% Reduction From Baseline in Number of Nocturnal Voids at 3 months. Started Feb 2011; status: completed.
02
Drugs
desmopressin
03
Conditions
nocturia
Beyond the preview
Go deeper on NCT01262456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01262456.